|
1
|
Bosch FX, Ribes J, Cleries R and Diaz M:
Epidemiology of hepatocellular carcinoma. Clin Liver Dis.
9:191–211. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lowe SW, Ruley HE, Jacks T and Housman DE:
p53-dependent apoptosis modulates the cytotoxicity of anticancer
agents. Cell. 74:957–967. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eisold S, Linnebacher M, Ryschich E, et
al: The effect of adenovirus expressing wild-type p53 on
5-fluorouracil chemosensitivity is related to p53 status in
pancreatic cancer cell lines. World J Gastroenterol. 10:3583–3589.
2004.PubMed/NCBI
|
|
4
|
Honda K, Sbisa E, Tullo A, et al: p53
mutation is a poor prognostic indicator for survival in patients
with hepatocellular carcinoma undergoing surgical tumour ablation.
Br J Cancer. 77:776–782. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hsia CC, Nakashima Y, Thorgeirsson SS, et
al: Correlation of immunohistochemical staining and mutations of
p53 in human hepatocellular carcinoma. Oncol Rep. 7:353–356.
2000.PubMed/NCBI
|
|
6
|
Clayman GL, Frank DK, Bruso PA and
Goepfert H: Adenovirus-mediated wild-type p53 gene transfer as a
surgical adjuvant in advanced head and neck cancers. Clin Cancer
Res. 5:1715–1722. 1999.PubMed/NCBI
|
|
7
|
Nemunaitis J, Swisher SG, Timmons T, et
al: Adenovirus-mediated p53 gene transfer in sequence with
cisplatin to tumors of patients with non-small-cell lung cancer. J
Clin Oncol. 18:609–622. 2000.PubMed/NCBI
|
|
8
|
Swisher SG, Roth JA, Komaki R, et al:
Induction of p53-regulated genes and tumor regression in lung
cancer patients after intratumoral delivery of adenoviral p53 (INGN
201) and radiation therapy. Clin Cancer Res. 9:93–101.
2003.PubMed/NCBI
|
|
9
|
Lang FF, Bruner JM, Fuller GN, et al:
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent
glioma: biological and clinical results. J Clin Oncol.
21:2508–2518. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
INGN 201. Ad-p53, Ad5CMV-p53, adenoviral
p53, p53 gene therapy - introgen, RPR/INGN 201. Drugs R D.
8:176–187. 2007.PubMed/NCBI
|
|
11
|
Drozdzik M, Qian C, Xie X, et al: Combined
gene therapy with suicide gene and interleukin-12 is more efficient
than therapy with one gene alone in a murine model of
hepatocellular carcinoma. J Hepatol. 32:279–286. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Su H, Lu R, Ding R and Kan YW:
Adeno-associated viral-mediated gene transfer to hepatoma:
thymidine kinase/interleukin 2 is more effective in tumor killing
in non-ganciclovir (GCV)-treated than in GCV-treated animals. Mol
Ther. 1:509–515. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duguid JR, Eble JN, Wilson TM and Kelley
MR: Differential cellular and subcellular expression of the human
multifunctional apurinic/apyrimidinic endonuclease (APE/ref-1) DNA
repair enzyme. Cancer Res. 55:6097–6102. 1995.PubMed/NCBI
|
|
14
|
Hanson S, Kim E and Deppert W: Redox
factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting
p53 tetramerization. Oncogene. 24:1641–1647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jayaraman L, Murthy KG, Zhu C, Curran T,
Xanthoudakis S and Prives C: Identification of redox/repair protein
Ref-1 as a potent activator of p53. Genes Dev. 11:558–570. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Herring CJ, West CM, Wilks DP, et al:
Levels of the DNA repair enzyme human apurinic/apyrimidinic
endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic
radiosensitivity of cervical cancers. Br J Cancer. 78:1128–1133.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moore DH, Michael H, Tritt R, Parsons SH
and Kelley MR: Alterations in the expression of the DNA
repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin
Cancer Res. 6:602–609. 2000.PubMed/NCBI
|
|
18
|
Robertson KA, Bullock HA, Xu Y, et al:
Altered expression of Ape1/ref-1 in germ cell tumors and
overexpression in NT2 cells confers resistance to bleomycin and
radiation. Cancer Res. 61:2220–2225. 2001.PubMed/NCBI
|
|
19
|
Bobola MS, Blank A, Berger MS, Stevens BA
and Silber JR: Apurinic/apyrimidinic endonuclease activity is
elevated in human adult gliomas. Clin Cancer Res. 7:3510–3518.
2001.PubMed/NCBI
|
|
20
|
Koukourakis MI, Giatromanolaki A,
Kakolyris S, et al: Nuclear expression of human
apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck
cancer is associated with resistance to chemoradiotherapy and poor
outcome. Int J Radiat Oncol Biol Phys. 50:27–36. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang D, Luo M and Kelley MR: Human
apurinic endonuclease 1 (APE1) expression and prognostic
significance in osteosarcoma: enhanced sensitivity of osteosarcoma
to DNA damaging agents using silencing RNA APE1 expression
inhibition. Mol Cancer Ther. 3:679–686. 2004.
|
|
22
|
Xiang DB, Chen ZT, Wang D, et al: Chimeric
adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity
of human colorectal cancer cells to radiotherapy in vitro and in
vivo. Cancer Gene Ther. 15:625–635. 2008. View Article : Google Scholar
|
|
23
|
Zhang Y, Wang J, Xiang D, Wang D and Xin
X: Alterations in the expression of the apurinic/apyrimidinic
endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer
and indentification of the therapeutic potential of APE1/Ref-1
inhibitor. Int J Oncol. 35:1069–1079. 2009.PubMed/NCBI
|
|
24
|
Wang D, Xiang DB, Yang XQ, et al: APE1
overexpression is associated with cisplatin resistance in non-small
cell lung cancer and targeted inhibition of APE1 enhances the
activity of cisplatin in A549 cells. Lung Cancer. 66:298–304. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Levine AJ, Momand J and Finlay CA: The p53
tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clayman GL, el-Naggar AK, Lippman SM, et
al: Adenovirus-mediated p53 gene transfer in patients with advanced
recurrent head and neck squamous cell carcinoma. J Clin Oncol.
16:2221–2232. 1998.PubMed/NCBI
|
|
28
|
Roth JA, Nguyen D, Lawrence DD, et al:
Retrovirus-mediated wild-type p53 gene transfer to tumors of
patients with lung cancer. Nat Med. 2:985–991. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Swisher SG, Roth JA, Nemunaitis J, et al:
Adenovirus-mediated p53 gene transfer in advanced non-small-cell
lung cancer. J Natl Cancer Inst. 91:763–771. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fleck O and Nielsen O: DNA repair. J Cell
Sci. 117:515–517. 2004. View Article : Google Scholar
|
|
31
|
Evans AR, Limp-Foster M and Kelley MR:
Going APE over ref-1. Mutat Res. 461:83–108. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xanthoudakis S, Smeyne RJ, Wallace JD and
Curran T: The redox/DNA repair protein, Ref-1, is essential for
early embryonic development in mice. Proc Natl Acad Sci USA.
93:8919–8923. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Larsen E, Meza TJ, Kleppa L and Klungland
A: Organ and cell specificity of base excision repair mutants in
mice. Mutat Res. 614:56–68. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Walker LJ, Craig RB, Harris AL and Hickson
ID: A role for the human DNA repair enzyme HAP1 in cellular
protection against DNA damaging agents and hypoxic stress. Nucleic
Acids Res. 22:4884–4889. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ono Y, Furuta T, Ohmoto T, Akiyama K and
Seki S: Stable expression in rat glioma cells of sense and
antisense nucleic acids to a human multifunctional DNA repair
enzyme, APEX nuclease. Mutat Res. 315:55–63. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen DS and Olkowski ZL: Biological
responses of human apurinic endonuclease to radiation-induced DNA
damage. Ann NY Acad Sci. 726:306–308. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gupta GP, Nguyen DX, Chiang AC, et al:
Mediators of vascular remodelling co-opted for sequential steps in
lung metastasis. Nature. 446:765–770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun X, Kanwar JR, Leung E, Lehnert K, Wang
D and Krissansen GW: Angiostatin enhances B7.1-mediated cancer
immunotherapy independently of effects on vascular endothelial
growth factor expression. Cancer Gene Ther. 8:719–727. 2001.
View Article : Google Scholar : PubMed/NCBI
|
